We will have limited operations from 15:00 Tuesday 24 December 2024 (AEDT) until Thursday 2 January 2025. Find out how to contact us during the holiday period.
Notice for cerliponase alfa (BioMarin Pharmaceuticals Australia Pty Ltd)
Active ingredients
cerliponase alfa
Date of review outcome
Lapse date
Type
Orphan drug
Dosage form(s)
Injection
Indication
For the treatment of neuronal ceroid lipofuscinosis type 2 (CLN2) disease, also known as tripeptidyl peptidase 1 (TPP1) deficiency.